BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Almac Group Concludes Commercial API Manufacturing Facility Expansion Plans


10/9/2012 9:25:21 AM

October 09, 2012 -- In response to client requirements, Almac’s expansion of their API manufacturing facility at its European Headquarters in Craigavon, UK is near completion, and will be operational by the end of the year. This upgrade includes installation of two 1,000L reactors and state-of-the-art pressure filter dryer, which allows production of GMP Active Pharmaceutical Ingredients (API) up to 150kg batch size.

Almac’s strategy to increase market share in late phase clinical development is reaping rewards, and clients are already seeing the advantages of having one constant manufacturing partner through each phase of clinical development. “Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development.” stated Denis Geffroy, VP Business Development. “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialisation.”

Clients can also leverage Almac’s API and Drug Product integrated offering where API manufacture and finished drug production is carried out on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity. Almac’s advantage of hosting all facilities on one site have led to the successful technology transfer of small molecule and peptide projects from lab development to large scale manufacture.

For further information, Almac will be exhibiting at the forthcoming CPhI (Booth 10E41) and AAPS (Booth 3027) conferences.

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new North American Headquarters located in Souderton PA.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->